On May 10, 2021, Novavax announced data from a preclinical study of the company’s combination quadrivalent seasonal flu vaccine (NanoFluﾙ) and COVID-19 vaccine candidate (NVX-CoV2373). The NanoFlu/NVX-CoV2373 combination vaccine demonstrated positive immune responses to both influenza and SARS-CoV-2. A pre-print of the manuscript was available at bioRxiv.org.